MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07 Submission of Matters to a Vote of Security
Holders.

On May11, 2017, Marinus Pharmaceuticals,Inc. (the Company) held
its Annual Meeting of Stockholders. The following proposals were
submitted by the Companys Board of Directors (Board) to a vote of
the Companys stockholders and the final results of the voting on
each proposal are noted below.

Proposal 1 Election of Directors

The stockholders elected the following individuals to serve as
ClassIII directors for a three-year term until the 2020 annual
meeting of stockholders and until their successors are elected
and qualified:

Proposal 2 Amendment to the Companys 2014 Equity Compensation
Plan (the Plan) increasing the maximum number of shares of common
stock available for issuance under the Plan to from 700,000 to
4,158,164, and further increasing the number of shares
of common stock available for issuance under the Plan to an
annual increase on January1 of each year until the expiration of
the Plan from the lesser of 1,120,000 common shares or 4% of the
total number of shares of the Companys capital stock calculated
on a common-equivalent basis and outstanding on that date or such
lesser number of shares as the Board may determine, to the lesser
of 2,000,000 common shares or 5% of the total number of shares
outstanding on that date or such lesser number of shares as the
Board may determine.

The stockholders approved the amendment of the Companys 2014
Equity Compensation Plan as follows:

Proposal 3 Ratification of the selection of KPMG LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017.

The stockholders ratified the appointment of KPMG LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017 as follows:

About MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) Recent Trading Information

MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) closed its last trading session up +0.02 at 1.34 with 114,116 shares trading hands.